Navan Inc. Class A Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Navan Inc. Class A Common Stock trades at $23.66 (market cap $6.22B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Navan Inc. Class A Common Stock is far larger — about 4.2× uniQure N.V. Ordinary Shares's market cap, and Navan Inc. Class A Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NAVN | QURE | |
|---|---|---|
Market Cap | $6.22B | $1.48B |
Volume | 2,173,244 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $30.58 | $70.59 |
52-Week Low | $8.51 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.57B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Navan (NAVN) trades at $23.9, up 1.44% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong revenue growth of 35% year-over-year in Q2 2027 to $233 million, beating earnings expectations, yet remains unprofitable with a net income margin of -42.11%. Recent developments include the acquisition of BoomPop and a partnership with Engine to expand its AI-powered travel platform.
The outlook is mixed: unanimous analyst buy ratings and a $30.56 price target suggest 27.5% upside, driven by growth execution. However, high debt, persistent losses, insider selling, and ongoing legal investigations pose significant risks. The stock's valuation appears stretched given current profitability challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →